Crescent Biopharma (CBIO) had its price target lowered by HC Wainwright from $25.00 to $22.00. They now have a "buy" rating on the stock.
Crescent Biopharma (CBIO) was given a new $29.00 price target by Stifel Nicolaus.
Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Crescent Biopharma (NASDAQ:CBIO) was upgraded by analysts at
Wall Street